818
Advertising Networks · New Zealand · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7 Premier Ave, Auckland, Auckland, 1022,...Website
www.818.co.nzRevenue
<$5 MillionIndustry
About 818
818 Org Chart
Is 818 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if 818 has recently received funding, and reach out quickly before it becomes old news!
Check out if 818 is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when 818 launches new products
Earning: See what the market has to say on 818 recently announced quarterly report
Click to see if 818 had a recent Job posting/layoffs
Funding: Get notified immidiatlly once 818 has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
818, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at 818
Recommended Actions
Reach out to Masked Content who joined 818 as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
818 is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
818 is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about 818.
818 Tech Stack
A closer look at the technologies used by 818
818 News & Media
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE
HEFEI, China, April 28, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved Phase IIb clinical trial of KPG-818 capsule for the treatment of moderate to severe cutaneous manifestations of systemic lupus erythematosus (SLE). About Cutaneous Manifestations of SLE SLE is a complex, heterogeneous, inflammatory, chronic autoimmune disease in which the body's immune systemKangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma
HEFEI, China, Feb. 25, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory multiple myeloma (RRMM). IND approval record on CDE official website KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It demonstrated high cereblon (CRBN) bKangpu Completed Bridging Clinical Study of KPG-818 in China
HEFEI, China, Sept. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China. The randomized, double-blind, placebo-controlled, and food effects (FE) study aimed to assess the safety and tolerability of multiple oral doses of KPG-818 in male and female healthy participants over a treatment period of 14 days and a follow-up period
Top Advertising Networks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding 818
818 818 Entertainment is a public relations agency that specializes in publicity for film, music, and television. They offer a range of services including unit publicity, campaign publicity, sports, events, talent tours, and coverage. Their intended clients include artists, filmmakers, and entertainment professionals seeking to enhance their public... Read More